Advertisement
News
Subscribe to MDT Magazine News

ItN Nanovation announces partnership with ThyssenKrupp Xervon Energy covering Nanocomp PP

September 29, 2010 2:33 am | by I-Micronews | Comments

Exclusive cooperation agreement for advanced nanoceramic technology used in power plants

REACH register to ensure traceability of nanomaterials

September 29, 2010 2:33 am | by I-Micronews | Comments

Ahead of a regulatory review next year, the Belgian EU Presidency is proposing to create a specific register for nanomaterials under the bloc's REACH chemicals regulation and wants to make it mandatory to label their presence in consumer products.

Doctors need to help patients prepare better for health decisions

September 28, 2010 11:32 pm | by EurekAlert | Comments

(University of Michigan) Twelve years ago, then 28-year-old graduate student Brian Zikmund-Fisher was forced into the toughest choice of his life: Die from a blood disorder within a few years or endure a bone marrow transplant that could cure him or kill him in weeks.

TOPICS:
Advertisement

<i>From the Bench: </i>Alfama shows carbon monoxide can be therapeutic, if they can deliver it

September 28, 2010 8:34 pm | by Mass High Tech: The Journal of New England Technology | Comments

Alfama Inc. sees carbon monoxide as a therapy for a significant number of medical conditions, including liver failure, rheumatoid arthritis, heart attack and gastric ulcers. The trick is in delivering CO to the disease site without causing the problems that most people associate with the gas.

TOPICS:

Nanotechnology Brings Personalized Therapy One Step Closer to Reality

September 28, 2010 4:32 pm | by AACR | Comments

DENVER — A novel technology can make nanoscale protein measurements, which scientists can use in clinical trials to learn how drugs work.

TOPICS:

c-Met May Be a Biomarker for Metastatic Hepatocellular Carcinoma

September 28, 2010 3:31 pm | by AACR | Comments

Tweet • c-Met activation linked with poor prognosis. • c-Met was highly overexpressed in metastatic liver cancer cells. DENVER — Targeting c-Met may be a promising personalized treatment method for approximately 45 percent of patients with hepatocellular carcinoma (HCC) who have...

TOPICS:

Regence to stop selling child-only health plans

September 28, 2010 2:45 pm | by RACHEL LA CORTE - Associated Press Writer - Associated Press | Comments

Regence BlueShield announced Tuesday that it will stop selling new child-only individual insurance policies by the end of this week.The move comes less than a week after several provisions of the federal health care overhaul went into effect, including one that prevents insurance companies from...

Women and Infants provides fertility preservation for childhood cancer survivors

September 28, 2010 1:35 pm | by EurekAlert | Comments

(Women & Infants Hospital) Unfortunately, the aggressive treatments for cancer may often render a child infertile. The likelihood that this will occur depends on the child's age, type of cancer and treatment plan. The Program for Fertility Preservation at Women & Infants Hospital...

TOPICS:
Advertisement

African-Americans Equally Likely to Benefit from Erlotinib and Other Targeted Lung Cancer Therapy

September 28, 2010 1:34 pm | by AACR | Comments

DENVER — African-American patients with non-small cell lung cancer are just as likely to display an epidermal growth factor receptor (EGFR) mutation in tumors as Caucasians, which suggests they are as likely to benefit from targeted therapies such as erlotinib.

TOPICS:

Novel Test Following Prostate Surgery Could Detect Cancer Recurrence Earlier

September 28, 2010 1:33 pm | by AACR | Comments

DENVER — A new test could reliably detect early increases in prostate specific antigen (PSA) levels — a biomarker commonly used to measure the recurrence of prostate cancer — in men who have undergone prostate cancer-treating surgery. Earlier detection of these rising levels would allow...

TOPICS:

Draft Guidance for Industry and FDA Staff - Class II Special Controls Guidance Document: Herpes Simplex Virus Types 1 and 2 Serological Assays

September 28, 2010 1:31 pm | by U.S. Food & Drug Administration | Comments

This special controls guidance document was developed to support the reclassification of the herpes simplex virus types 1 and 2 (HSV 1 and 2) serological assays into class II. HSV serological assays are devices that consist of antigens and antisera...

TOPICS:

Federal Register: Microbiology Devices; Reclassification of Herpes Simplex Virus Types 1 and 2 Serological Assays; Confirmation of Effective Date.

September 28, 2010 1:31 pm | by U.S. Food & Drug Administration | Comments

The FDA is is confirming the effective date of December 7, 2009, for the direct final rule that appeared in the Federal Register of August 25, 2009 (74 FR 42773). The direct final rule corrects the regulation classifying herpes simplex virus (HSV)...

TOPICS:

Federal Register: Immunology and Microbiology Devices; Reclassification of Herpes Simplex Virus Serological Assay Device.

September 28, 2010 1:31 pm | by U.S. Food & Drug Administration | Comments

The FDA is proposing to amend the special controls for the herpes simplex virus (HSV) serologicalassay device type, which is classified as class II (special controls). These device types are devices that consist of antigens and antisera used in various...

TOPICS:

Method to Detect Bladder Cancer Earlier is Under Development

September 28, 2010 12:31 pm | by AACR | Comments

DENVER — Scientists may have discovered a way to diagnose bladder cancer at its earliest and, therefore, most treatable stages by measuring the presence or absence of microRNA using already available laboratory tests.

TOPICS:

AACR Congratulates Member Napoleone Ferrara, M.D., on Receiving the Lasker-DeBakey Clinical Medical Research Award

September 28, 2010 12:31 pm | by AACR | Comments

PHILADELPHIA — The American Association for Cancer Research congratulates its member Napoleone Ferrara, M.D., on receiving the 2010 Lasker-DeBakey Clinical Medical Research Award. Ferrara, a member of the AACR since 2000, received this prestigious award for the discovery of vascular...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading